SOX9 and breast carcinoma: By ranking them by their activity, we found that SOX9 was among the most enriched TFs in the metastatic tumoroids (Fig. 4e and Supplementary Fig. 4a, b) and was expressed in breast cancer (Fig. 4f and Supplementary Fig. 4c).